Munich - Delayed Quote EUR

CytoDyn Inc (296.MU)

Compare
0.1990
+0.0180
+(9.94%)
As of 12:04:45 PM GMT+1. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
5/31/2024
5/31/2023
5/31/2022
5/31/2021
Total Revenue
--
--
--
266.0000
--
Cost of Revenue
--
--
20,633.0000
53.0000
--
Gross Profit
--
--
-20,633.0000
213.0000
--
Operating Expense
-8,682.0000
18,058.0000
19,943.0000
145,617.0000
89,520.0000
Operating Income
8,682.0000
-18,058.0000
-40,576.0000
-145,404.0000
-89,520.0000
Net Non Operating Interest Income Expense
-13,051.0000
-18,173.0000
-30,498.0000
-61,563.0000
-61,241.0000
Other Income Expense
-9,879.0000
-13,610.0000
-8,750.0000
-3,853.0000
-25,704.0000
Pretax Income
-14,248.0000
-49,841.0000
-79,824.0000
-210,820.0000
-176,465.0000
Net Income Common Stockholders
-15,731.0000
-51,324.0000
-86,736.0000
-212,448.0000
-178,152.0000
Diluted NI Available to Com Stockholders
-15,731.0000
-51,324.0000
-86,736.0000
-212,448.0000
-178,152.0000
Basic EPS
-0.02
-0.05
-0.10
-0.31
-0.30
Diluted EPS
-0.02
-0.05
-0.10
-0.31
-0.30
Basic Average Shares
1,087,907.5000
969,509.0000
836,528.0000
676,900.0000
587,590.0000
Diluted Average Shares
1,101,010.0000
969,509.0000
836,528.0000
676,900.0000
587,590.0000
Total Operating Income as Reported
8,682.0000
-18,058.0000
-40,576.0000
-145,404.0000
-104,596.0000
Total Expenses
-8,682.0000
18,058.0000
40,576.0000
145,670.0000
89,520.0000
Net Income from Continuing & Discontinued Operation
-14,248.0000
-49,841.0000
-79,824.0000
-210,820.0000
-176,465.0000
Normalized Income
-4,369.0000
-36,231.0000
-71,074.0000
-206,967.0000
-150,761.0000
Interest Income
--
--
--
--
2.0000
Interest Expense
5,396.0000
5,735.0000
6,750.0000
15,066.0000
61,031.0000
Net Interest Income
-13,051.0000
-18,173.0000
-30,498.0000
-61,563.0000
-61,241.0000
EBIT
-8,852.0000
-44,106.0000
-73,074.0000
-195,754.0000
-115,434.0000
EBITDA
-8,832.0000
-44,077.0000
-72,899.0000
-194,973.0000
-113,637.0000
Reconciled Cost of Revenue
--
--
20,633.0000
53.0000
--
Reconciled Depreciation
20.0000
29.0000
175.0000
781.0000
1,797.0000
Net Income from Continuing Operation Net Minority Interest
-14,248.0000
-49,841.0000
-79,824.0000
-210,820.0000
-176,465.0000
Total Unusual Items Excluding Goodwill
-9,879.0000
-13,610.0000
-8,750.0000
-3,853.0000
-25,704.0000
Total Unusual Items
-9,879.0000
-13,610.0000
-8,750.0000
-3,853.0000
-25,704.0000
Normalized EBITDA
1,047.0000
-30,467.0000
-64,149.0000
-191,120.0000
-87,933.0000
5/31/2021 - 6/5/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ENGN enGene Holdings Inc.
6.77
-4.72%
 
RYTM Rhythm Pharmaceuticals, Inc.
59.45
+0.39%
 
NRIX Nurix Therapeutics, Inc.
19.72
-1.47%
 
ABSI Absci Corporation
3.7050
-3.01%
 
EYEN Eyenovia, Inc.
0.0346
-0.86%
 
NTLA Intellia Therapeutics, Inc.
10.32
-1.86%
 
ATHE Alterity Therapeutics Limited
4.9050
+7.33%
 
REGN Regeneron Pharmaceuticals, Inc.
673.14
-1.46%
 
RXRX Recursion Pharmaceuticals, Inc.
7.26
-5.66%
 
TNXP Tonix Pharmaceuticals Holding Corp.
0.4296
+14.56%